Kala Pharmaceuticals (NASDAQ:KALA) Announces Earnings Results

Kala Pharmaceuticals (NASDAQ:KALA) announced its quarterly earnings data on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01), Fidelity Earnings reports. The business had revenue of $1.45 million during the quarter, compared to analysts’ expectations of $3.56 million.

Shares of KALA stock traded up $0.40 on Friday, hitting $4.11. 374,000 shares of the stock were exchanged, compared to its average volume of 249,192. The firm’s 50 day moving average is $3.84 and its two-hundred day moving average is $5.11. Kala Pharmaceuticals has a one year low of $3.24 and a one year high of $9.25. The firm has a market capitalization of $126.17 million, a PE ratio of -1.66 and a beta of 2.13. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16.

KALA has been the subject of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $51.00 price objective on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price objective on Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Zacks Investment Research upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Wednesday. Oppenheimer set a $9.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright cut their price target on Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.54.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: Analyzing a company’s cash flow statement

Earnings History for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit